Features | Partner Sites | Information | LinkXpress
Sign In
CARDIOSTIM
Primedic
Ampronix

Zoll Acquires Intellectual Assets of Coaxia

By HospiMedica International staff writers
Posted on 15 Jul 2013
ZOLL (Chelmsford, MA, USA) has purchased the assets of CoAxia (Maple Grove, MN, USA), an early revenue stage medical device company that provides catheter-based perfusion augmentation therapies.

The core application ofCoAxia’s catheter technology, distributed under the trade names NeuroFlo and FloControl, involves the redistribution of blood flow from the lower extremities to support brain function during cerebral ischemia resulting from vasospasm, following subarachnoid hemorrhage. CoAxia did not have the funds to continue development after its de novo petition for the NeuroFlo catheter was rejected by the US Food and Drug Administration (FDA) for acute ischemic stroke. Zoll, however, still sees opportunity for the device and plans to design a new pivotal trial to take before the FDA.

Both NeuroFlo and FloControl blood flow redistribution technology use dual balloons to create temporary partial obstruction in the descending aorta. This technique causes a redistribution of cardiac output from the lower extremities to the cerebral vasculature without significantly increasing arterial blood pressure. The acquisition of the intellectual property also includes several key patents on cerebral perfusion augmentation as well as numerous other patents relevant to other various vascular procedures. Financial terms of the purchase were not disclosed.

“NeuroFlo technology has the potential to address a large portion of the population who suffer cerebral ischemia, offering a significant benefit to patients and the healthcare system,” said James Palazzolo, president of Zoll. “Our task is to continue to develop the significant body of clinical evidence started by CoAxia demonstrating the safety and efficacy of the NeuroFlo catheter and, in the end, do what is necessary for it to be a standard treatment option for hundreds of thousands of stroke patients worldwide.”

The acquisition of CoAxia’s intellectual property also offers synergy with Zoll’s acute critical care portfolio of products such as temperature management, which may reduce reperfusion injury following ischemia by using balloon catheters. The devices could also offer significant potential applications in blood flow redistribution for trauma, cardiac arrest, coronary procedures, surgical blood loss, and renal perfusion.

Related Links:

ZOLL
CoAxia



Channels

Surgical Techniques

view channel
3-D Printing Helps Rehearse Complex Brain Procedures

3-D Printing Helps Rehearse Complex Brain Procedures

A new study describes how custom, high–fidelity three-dimensional (3-D) printed models of brain vessel malformations can be used to rehearse pediatric surgical procedures. Researchers at Boston Children’s... Read more

Women's Health

view channel

Fetal ECG Readings Offer No Advantage During Labor

A new technology that provides electrocardiogram (ECG) readings of the fetus heart during the birth process offers no advantages over conventional monitoring, according to a new study. Researchers at the US National Institute of Child Health and Human Development (NICHD; Bethesda, MD, USA), the University of Texas Medical... Read more

Hospital News

view channel
Image: The future site of the Springdale ACH campus on I-49, across from Arvest Ballpark (Photo courtesy of ACH).

Arkansas Children's Hospital to Develop Springdale Facility

Arkansas Children's Hospital (ACH; Little Rock, USA) has unveiled plans to develop a new hospital campus in Springdale, which will involve an investment of USD 184 million during the next five years.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.